Indication

As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.

Medicine details

Medicine name:
osimertinib (Tagrisso)
SMC ID:
SMC2382
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Publication due date:
08 November 2021
SMC meeting date:
05 October 2021
Patient group submission deadline:
06 September 2021